Cover Image

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand

(1) Background: Resistant <i>Pseudomonas aeruginosa</i> (PA) infections have limited treatment options. Data on the activity of ceftolozane-tazobactam (C-T) against PA in Thailand are limited. Objectives: The objective of this study was to identify the in vitro activity of C-T against ge...

Full description

Saved in:

Bibliographic Details
Main Authors:	Woraphot Tantisiriwat (Author), Jirawat Buppanharun (Author), Chatchai Ekpanyaskul (Author), Kwanchai Onruang (Author), Thitiya Yungyuen (Author), Pattarachai Kiratisin (Author), Somchai Santiwatanakul (Author)
Format:	Book
Published:	MDPI AG, 2022-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>
by: Worapong Nasomsong, et al.
Published: (2022)

Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> in an Academic Medical Center in Thailand
by: Taniya Paiboonvong, et al.
Published: (2022)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Aisling R. Caffrey, et al.
Published: (2022)

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting
by: Francesco Venuti, et al.
Published: (2023)

Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Enterobacterales</i> from Five Latin American Countries
by: Juan Carlos García-Betancur, et al.
Published: (2022)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
by: Silvia Garazzino, et al.
Published: (2020)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022)

In Vitro Activity of Ceftolozane-Tazobactam against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa
by: Olga Perovic, et al.
Published: (2023)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023)

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
by: Hakeam A. Hakeam, et al.
Published: (2022)

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia
by: Ahmed Zikri, et al.
Published: (2019)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020)

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition
by: Jan Thomas De Pourcq, et al.
Published: (2024)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
by: María José Contreras-Gómez, et al.
Published: (2022)

BIChromET: A Chromogenic Culture Medium for Detection of Piperacillin/Tazobactam and Cefepime Resistance in <i>Pseudomonas aeruginosa</i>
by: José Manuel Ortiz de la Rosa, et al.
Published: (2023)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical P. aeruginosa isolates collected in the Middle East - SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
by: Z. S. Khankhel, et al.
Published: (2022)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
by: Skalweit MJ
Published: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
by: Giancola SE, et al.
Published: (2016)

<i>Pseudomonas aeruginosa</i> Biofilm Formation, Infections and Treatments
Published: (2021)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020)

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
by: Laura Butragueño-Laiseca, et al.
Published: (2020)

Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
by: Xing Tan, et al.
Published: (2019)

Association of <i>bla</i><sub>VIM-2</sub>, <i>bla</i><sub>PDC-35</sub>, <i>bla</i><sub>OXA-10,</sub> <i>bla</i><sub>OXA-488</sub> and <i>bla</i><sub>VEB-9</sub> β-Lactamase Genes with Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Mazen A. Sid Ahmed, et al.
Published: (2022)

Treatment Heterogeneity in <i>Pseudomonas aeruginosa</i> Pneumonia
by: Aisling R. Caffrey, et al.
Published: (2022)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
by: Li-Ting Wang, et al.
Published: (2021)

Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
by: Jessica R. Tait, et al.
Published: (2022)

Antimicrobial Treatment of <i>Pseudomonas aeruginosa</i> Severe Sepsis
by: Johnny Zakhour, et al.
Published: (2022)

The Basis for Natural Multiresistance to Phage in <i>Pseudomonas aeruginosa</i>
by: Christine Pourcel, et al.
Published: (2020)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020)

In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals
by: Nezar M. Bahabri, et al.
Published: (2022)

Spiramycin Disarms <i>Pseudomonas aeruginosa</i> without Inhibiting Growth
by: Matteo Calcagnile, et al.
Published: (2023)

Bacteriophage-Antibiotic Combination Therapy against <i>Pseudomonas aeruginosa</i>
by: Guillermo Santamaría-Corral, et al.
Published: (2023)

Sub-Inhibitory Antibiotic Exposure and Virulence in <i>Pseudomonas aeruginosa</i>
by: Charlotte Nolan, et al.
Published: (2021)